Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCLD-CoV19
- Development stage
- Phase 2
- Lead developer
- Cellid
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AdCLD-CoV19 is a replication-deficient adenoviral vector vaccine developed by the South Korean biotechnology company Cellid for the prevention of COVID-19. The vaccine utilizes Cellid's proprietary AdCLD platform, which employs a human adenovirus vector to deliver the genetic code for the SARS-CoV-2 spike protein into host cells, thereby stimulating both antibody production and T-cell responses. Clinical development has included the original strain candidate and a variant-specific version, AdCLD-CoV19-1 OMI, targeting the Omicron variant. It has been investigated in Phase 1 and Phase 2 clinical trials as a single-dose or two-dose regimen and as a booster.
- Other names
- AdCLD-CoV19-1 OMIAdCLD-CoV-19-1 OMIAdCLD-CoV 19-1 OMI
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on AdCLD-CoV19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCLD-CoV19.